我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
24
4 进行中
药物批准
31
批准总数
监管机构
4
监管机构数
成立时间
N/A
进行中（未招募）
2
8.3%
已完成
16
66.7%
尚未招募
招募中
16.7%
NMPA
National Medical Products Administration
1
FDA
Food and Drug Administration
PHILIPPINES
Philippines FDA
20
NPRA
National Pharmaceutical Regulatory Agency
6
- The Indian Patent Office revoked Novartis' patent for Vymada (Entresto), a heart failure drug generating $7.8 billion in global sales, citing lack of novelty and inventive step. - The ruling removes legal barriers for domestic pharmaceutical companies including Natco, Torrent Pharma, MSN Labs, and Eris Lifesciences to market generic versions. - The decision invoked Section 3(d) of India's Patents Act, designed to prevent "evergreening" of patents, marking a rare application of this provision in recent years. - Industry experts expect increased competition to significantly reduce treatment costs for Indian patients with hypertension and heart failure.
